BioCentury
ARTICLE | Clinical News

Nesina alogliptin regulatory update

June 2, 2014 7:00 AM UTC

Takeda said Japan's Ministry of Health, Labor and Welfare (MHLW) approved an application to expand the label of Type II diabetes drug Nesina alogliptin to include concomitant therapy with all oral anti-diabetic agents and insulin. Nesina was previously approved in Japan in patients with Type II diabetes in combination with alpha-glucosidase inhibitors, thiazolidinediones, sulfonylurea or biguanide.

Furiex co-developed alogliptin, an oral dipeptidyl peptidase-4 (DPP-4) inhibitor, with Syrrx Inc., which Takeda acquired in 2005. Forest Laboratories Inc. (NYSE:FRX, New York, N.Y.) is acquiring Furiex in a deal slated to close this quarter or next. Forest said it plans to sell Furiex's royalty stream from alogliptin to Royalty Pharma (New York, N.Y.) in a concurrent deal (see BioCentury, May 5). Actavis plc (NYSE:ACT, Dublin, Ireland) is acquiring Forest in a cash and stock deal expected to close in mid-2014 (see BioCentury, Feb. 24 & May 19). ...